675 related articles for article (PubMed ID: 30309758)
21. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Al-Sawaf O; Zhang C; Tandon M; Sinha A; Fink AM; Robrecht S; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Tausch E; Schary W; Ritgen M; Wendtner CM; Kreuzer KA; Eichhorst B; Stilgenbauer S; Hallek M; Fischer K
Lancet Oncol; 2020 Sep; 21(9):1188-1200. PubMed ID: 32888452
[TBL] [Abstract][Full Text] [Related]
22. End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA.
Kostakoglu L; Martelli M; Sehn LH; Belada D; Carella AM; Chua N; Gonzalez-Barca E; Hong X; Pinto A; Shi Y; Tatsumi Y; Knapp A; Mattiello F; Nielsen T; Sahin D; Sellam G; Oestergaard MZ; Vitolo U; Trněný M
Blood Adv; 2021 Mar; 5(5):1283-1290. PubMed ID: 33651099
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
[TBL] [Abstract][Full Text] [Related]
24. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.
Frontzek F; Ziepert M; Nickelsen M; Altmann B; Glass B; Haenel M; Truemper L; Held G; Bentz M; Borchmann P; Dreyling M; Viardot A; Kroschinsky FP; Metzner B; Staiger AM; Horn H; Ott G; Rosenwald A; Loeffler M; Lenz G; Schmitz N
Lancet Haematol; 2021 Apr; 8(4):e267-e277. PubMed ID: 33667420
[TBL] [Abstract][Full Text] [Related]
25. Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma.
Davies A; Trask P; Demeter J; Florschütz A; Hänel M; Kinoshita T; Pettengell R; Quach H; Robinson S; Sadullah S; Sancho JM; Udvardy M; Witzens-Harig M; Knapp A; Liu W
Ann Hematol; 2020 Dec; 99(12):2837-2846. PubMed ID: 32314038
[TBL] [Abstract][Full Text] [Related]
26. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
Tilly H; Morschhauser F; Bartlett NL; Mehta A; Salles G; Haioun C; Munoz J; Chen AI; Kolibaba K; Lu D; Yan M; Penuel E; Hirata J; Lee C; Sharman JP
Lancet Oncol; 2019 Jul; 20(7):998-1010. PubMed ID: 31101489
[TBL] [Abstract][Full Text] [Related]
27. Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma.
Batlevi CL; Sha F; Alperovich A; Ni A; Smith K; Ying Z; Gerecitano JF; Hamlin PA; Horwitz SM; Joffe E; Kumar A; Matasar MJ; Moskowitz AJ; Moskowitz CH; Noy A; Owens C; Palomba LM; Straus D; von Keudell G; Zelenetz AD; Seshan VE; Luminari S; Marcheselli L; Federico M; Younes A
Eur J Cancer; 2020 Feb; 126():78-90. PubMed ID: 31927165
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma.
Younes A; Burke JM; Diefenbach C; Ferrari S; Khan C; Sharman JP; Tani M; Ujjani C; Vitolo U; Yuen S; Raval A; Shivhare M; Nielsen TG; Sellam G; Gilbertson M
Blood Adv; 2022 Oct; 6(20):5659-5667. PubMed ID: 35359000
[TBL] [Abstract][Full Text] [Related]
29. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
30. Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.
Bachy E; Seymour JF; Feugier P; Offner F; López-Guillermo A; Belada D; Xerri L; Catalano JV; Brice P; Lemonnier F; Martin A; Casasnovas O; Pedersen LM; Dorvaux V; Simpson D; Leppa S; Gabarre J; da Silva MG; Glaisner S; Ysebaert L; Vekhoff A; Intragumtornchai T; Le Gouill S; Lister A; Estell JA; Milone G; Sonet A; Farhi J; Zeuner H; Tilly H; Salles G
J Clin Oncol; 2019 Nov; 37(31):2815-2824. PubMed ID: 31339826
[TBL] [Abstract][Full Text] [Related]
31. Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy.
Jamois C; Gibiansky E; Gibiansky L; Buchheit V; Sahin D; Cartron G; Marcus R; Hiddemann W; Seymour JF; Strefford JC; Hargreaves CE; Meneses-Lorente G; Frey N; Fingerle-Rowson G
Br J Clin Pharmacol; 2019 Jul; 85(7):1495-1506. PubMed ID: 30866056
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma.
Spencer SJ; Guzauskas GF; FeLizzi F; Launonen A; Dawson K; Veenstra DL; Masaquel A
J Manag Care Spec Pharm; 2021 May; 27(5):615-624. PubMed ID: 33586513
[No Abstract] [Full Text] [Related]
33. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
34. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
Morschhauser F; Flinn IW; Advani R; Sehn LH; Diefenbach C; Kolibaba K; Press OW; Salles G; Tilly H; Chen AI; Assouline S; Cheson BD; Dreyling M; Hagenbeek A; Zinzani PL; Jones S; Cheng J; Lu D; Penuel E; Hirata J; Wenger M; Chu YW; Sharman J
Lancet Haematol; 2019 May; 6(5):e254-e265. PubMed ID: 30935953
[TBL] [Abstract][Full Text] [Related]
35. First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis.
Pouyiourou M; Meyer A; Stroux A; Viardot A; La Rosée P; Maschmeyer G; Kämpfe D; Kahl C; Vucinic V; Monecke A; Hirt C; Weber T; Meissner J; Witzens-Harig M; Böttcher S; Schmalenberg H; Marks R; Prange-Krex G; Kroschinsky F; Hauf E; Keller U; Koch K; Klapper W; Herold M; Scholz CW;
Ann Hematol; 2020 Dec; 99(12):2821-2829. PubMed ID: 32734548
[TBL] [Abstract][Full Text] [Related]
36. End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial.
Kato K; Izutsu K; Nishikori M; Shibayama H; Maeda Y; Yoshimura K; Tateishi U; Miyamoto T; Matsuda Y; Ishikawa J; Rai S; Takahashi T; Yamauchi T; Matsumura I; Akashi K; Kanakura Y; Suzumiya J
Int J Hematol; 2024 Jun; 119(6):677-685. PubMed ID: 38519820
[TBL] [Abstract][Full Text] [Related]
37. Safe administration of rituximab for follicular lymphoma after obinutuzumab infusion-related reaction.
Hara T; Suzuki R; Ohno A; Yamakawa K; Yamagishi Y; Sugiyama Y; Sobajima T; Yamada R; Matsumoto R; Ikeda Y; Murayama M; Tsurumi H
Int J Hematol; 2020 Apr; 111(4):585-590. PubMed ID: 31848991
[TBL] [Abstract][Full Text] [Related]
38. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.
Cramer P; Fürstenau M; Robrecht S; Giza A; Zhang C; Fink AM; Fischer K; Langerbeins P; Al-Sawaf O; Tausch E; Schneider C; Schetelig J; Dreger P; Böttcher S; Kreuzer KA; Schilhabel A; Ritgen M; Brüggemann M; Kneba M; Stilgenbauer S; Eichhorst B; Hallek M
Lancet Haematol; 2022 Oct; 9(10):e745-e755. PubMed ID: 35988545
[TBL] [Abstract][Full Text] [Related]
39. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.
Cashen AF; Dehdashti F; Luo J; Homb A; Siegel BA; Bartlett NL
J Nucl Med; 2011 Mar; 52(3):386-92. PubMed ID: 21321279
[TBL] [Abstract][Full Text] [Related]
40. Impact of complete surgical resection on outcome in aggressive non-Hodgkin lymphoma treated with immunochemotherapy.
Schmitz C; Rekowski J; Müller SP; Farsijani N; Hertenstein B; Franzius C; von Verschuer U; La Rosée P; Freesmeyer M; Wilop S; Krohn T; Raghavachar A; Ganser A; Bengel FM; Prange-Krex G; Kroschinsky F; Kotzerke J; Giagounidis A; Dührsen U; Hüttmann A
Cancer Med; 2020 Nov; 9(22):8386-8396. PubMed ID: 32926763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]